I'll refer you to my blog.
The FDA has approved the eFlow for CF use only. No other respiratory disease has FDA approval for eFlow use.
My physician attended the NACF and the eFlow was spoken of highly there. In fact, eFlow is being used in clinical trials for several CF drugs coming to market including Aztreonam.
If you go to the German PARI website, and select english for your language, you can see all the studies that were conducted with the eFlow and CF meds. Serum levels were proven to be identical with the eFlow and the PARI ProNeb using both TOBI and Pulmozyme. Particle size has been proven to be more often a repirable size with the eFlow than any other compressor on the market.
The data is solid.
Unfortunately, the US FDA works differently than the equivalent body in the US and therefore PARI cannot publish these clinical studies on its US website (durable medical equipment manufacturers may not publish the use of particular medication with their device). It's a rediculous rule but it can be skirted through the internet.
I'm hoping to get a hold of the studies on my own, however, so I can post them here. Again, I'll refer you back to my blog for when I get a hold of those studies.
If you want in vitro and in vivo trial data other than what is on the German PARI site, contact SourceCF. They can get you a copy of published, well controlled studies that have been conducted with the eFlow.
What were the reasons that these physicians and respiratory therapists gave to not use the eFlow?
